drugset / Trial / NCT00525564

Effects of Salmeterol on Walking Capacity in Patients With COPD

NCT00525564

Phase 4 Completed 28 enrolled Laval University GlaxoSmithKline · collab
RandomizedCrossoverDouble-blindTreatment

Summary

This study was designed to test the following hypothesis: The acute changes in exercise tolerance during the endurance shuttle walk will be greater with salmeterol compared to placebo in patients with chronic obstructive pulmonary disease.

Timeline

Start
2006-05
Primary completion
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Salmeterol Other / unclassified 50 ug Inhaled